<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371035">
  <stage>Registered</stage>
  <submitdate>3/08/2016</submitdate>
  <approvaldate>8/08/2016</approvaldate>
  <actrnumber>ACTRN12616001055493</actrnumber>
  <trial_identification>
    <studytitle>The Food Obstruction in Oesophagus and Drugs Study: A Double Blinded Randomised Control Trial of Glucagon and Glyceryl Trinitrate Versus Placebo In Soft Food Bolus Impactions</studytitle>
    <scientifictitle>The Food Obstruction in Oesophagus and Drugs Study: A Double Blinded Randomised Control Trial of Glucagon and Glyceryl Trinitrate Versus Placebo In Soft Food Bolus Oesophageal Impactions </scientifictitle>
    <utrn>U1111-1185-0289
</utrn>
    <trialacronym>FOODS</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Soft food bolus impaction</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Glucagon 2mg intravenous + Glyceryl trinitrate 600mg orally administered simultaneously as a single administration

No strategy to monitor adherence is necessary as drugs will be administered by trained nursing staff.  </interventions>
    <comparator>Intravenous normal saline + glucose disintegrating placebo tablet orally</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical resolution of impaction by 30 minutes post administration of drugs as defined by:
a.	Ability to tolerate food and fluids without regurgitation
b.	No regurgitation of secretions
c.	Clinical gestalt of senior ED doctor
</outcome>
      <timepoint>30 minutes from administration of drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Endoscopy rate which will be calculated by checking each participant's medical record for endoscopy records </outcome>
      <timepoint>48 hours post first presentation to the ED</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evidence of oesophageal pathology whether by direct visualisation on endoscopy or subsequent histopathological examination of biopsy specimens </outcome>
      <timepoint>3 months post first presentation to the ED</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a.	Patients with first presentation of soft food bolus impaction
b.	Patients above or equal to 18 years old
c.	Patients capable of furnishing informed consent
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a.	Known oesophageal malignancy or structural abnormalities
b.	Previous presentation with soft food bolus oesophageal impaction
c.	Known allergy or intolerance to glucagon or GTN
d.	Extrinsic or intrinsic airway compromise
e.	Oesophageal impaction with inedible or hard foods (e.g. bones, pills, nails)
f.	Preload dependent cardiovascular physiology (e.g. severe aortic stenosis, hypotension)
g.	Known insulinoma, pheochromocytoma or glucagonoma
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>Manual shuffling of envelopes</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Sample size of 580 required to demonstrate non-inferiority of drugs regimen with placebo with an alpha of 10% and a beta of 80% assuming a control success rate of 8% and a non-inferiority limit of 5%. The control success rate is based on retrospective data generated from the same state.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>12/01/2018</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/09/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>580</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Fiona Stanley Hospital</primarysponsorname>
    <primarysponsoraddress>11 Robin Warren Drive
Murdoch WA 6150</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Alwin Lian</fundingname>
      <fundingaddress>c/o 
Royal Perth Hospital
197 Wellington Street
Perth 6000 WA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Richard Holman</fundingname>
      <fundingaddress>c/o 
Fiona Stanley Hospital 
11 Robin Warren Drive, 
Murdoch 6150 WA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Perth Hospital</fundingname>
      <fundingaddress>197 Wellington Street
Perth WA 6000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Fiona Stanley Hospital</fundingname>
      <fundingaddress>11 Robin Warren Drive
Murdoch WA 6150</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Sir Charles Gairdner Hospital</fundingname>
      <fundingaddress>Hospital Ave
Nedlands WA 6009
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The project aims to determine if the two commonly used drug regimens for soft food impactions in the oesophagus are better than placebo for passage of the obstructing bolus. 

Retrospective data from small and poorly-designed studies have led to the recommendations for the trial of glucagon, glyceryl trinitrate (GTN) or a combination of both in soft food bolus impactions as first line management prior to endoscopy. Retrospective data from a recent audit carried out at Freemantle has demonstrated that the rate of clinical resolution was not appreciably different between patients treated with drugs and patients not treated with drugs and that a strategy of proceeding straight to endoscopy might be preferable 

In order to definitively answer the question, we propose to prospectively assign patients to either a drug regimen of a) glucagon and GTN or b) placebo and observe the outcomes after 30 minutes after which the pharmacological properties of the drugs excludes a drug effect. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital HREC</ethicname>
      <ethicaddress>Royal Perth Hospital
197 Wellington Street
Perth WA 6000  </ethicaddress>
      <ethicapprovaldate>25/05/2016</ethicapprovaldate>
      <hrec>2016-067</hrec>
      <ethicsubmitdate>27/04/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Alwin Lian</name>
      <address>c/o RPH
Wellington Street
Perth WA 6000</address>
      <phone>+61425876842</phone>
      <fax />
      <email>alwin.lian@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alwin Lian</name>
      <address>c/o RPH
Wellington Street
Perth WA 6000</address>
      <phone>+61425876842</phone>
      <fax />
      <email>alwin.lian@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alwin Lian</name>
      <address>c/o RPH
Wellington Street
Perth WA 6000</address>
      <phone>+61425876842</phone>
      <fax />
      <email>alwin.lian@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alwin Lian</name>
      <address>c/o RPH
Wellington Street
Perth WA 6000</address>
      <phone>+61425876842</phone>
      <fax />
      <email>alwin.lian@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>